IHH's portfolio of brands include Acibadem, Mount Elizabeth, Prince Court, Gleneagles, Fortis, Pantai, Parkway and IMU, offering patients comprehensive and personalized care ranging from primary to quaternary services, including laboratories, diagnostics, imaging and rehabilitation. The company is actively seeking acquisitions in new markets such as Indonesia and Vietnam under its new CEO Prem Kumar Nair, who took over in October.
Cyborg Score Rationale
IHH maintains a substantial market cap of approximately 23.9 billion SGD and trades at a PE ratio of 33.88, reflecting investor confidence despite recent market underperformance. The company's diversified geographic footprint and strong brand portfolio provide resilience, though growth rates have moderated in recent reporting periods.
Top Insights
Operates 80+ hospitals across 10 countries with presence in Singapore, Malaysia, India, Greater China, Turkey, Europe and Southeast Asia
Provides full-spectrum healthcare from primary care through quaternary services including organ transplants, with ancillary diagnostics and rehabilitation
Recently under new CEO leadership pursuing geographic expansion into Indonesia and Vietnam markets
Market cap of ~23.9B SGD with 1.41% dividend yield
Named Competitors
Raffles Medical Group — Singapore-based healthcare provider with smaller footprint
Thomson Medical Group — Singapore healthcare operator with specialist focus